MX9401191A - Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
MX9401191A
MX9401191A MX9401191A MX9401191A MX9401191A MX 9401191 A MX9401191 A MX 9401191A MX 9401191 A MX9401191 A MX 9401191A MX 9401191 A MX9401191 A MX 9401191A MX 9401191 A MX9401191 A MX 9401191A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutical compositions
sulfamoil
procedure
contain
Prior art date
Application number
MX9401191A
Other languages
English (en)
Spanish (es)
Inventor
Claudine Serrradeil-Le
Gerard Valette
Bernard Crhistophe
Loic Foulon
Alain Pellet
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Publication of MX9401191A publication Critical patent/MX9401191A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX9401191A 1993-02-15 1994-02-15 Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. MX9401191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9301686A FR2701480B1 (fr) 1993-02-15 1993-02-15 Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
MX9401191A true MX9401191A (es) 1994-08-31

Family

ID=9444071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9401191A MX9401191A (es) 1993-02-15 1994-02-15 Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (23)

Country Link
US (2) US5506258A (ru)
EP (1) EP0614911B1 (ru)
JP (1) JP2994546B2 (ru)
KR (1) KR940019682A (ru)
CN (1) CN1104634A (ru)
AT (1) ATE179430T1 (ru)
AU (1) AU673398B2 (ru)
CA (1) CA2115631A1 (ru)
DE (1) DE69418083T2 (ru)
DK (1) DK0614911T3 (ru)
ES (1) ES2132351T3 (ru)
FI (1) FI940680A (ru)
FR (1) FR2701480B1 (ru)
GR (1) GR3030243T3 (ru)
HU (1) HUT66960A (ru)
IL (1) IL108649A (ru)
MX (1) MX9401191A (ru)
NO (1) NO304313B1 (ru)
NZ (1) NZ250878A (ru)
PH (1) PH30887A (ru)
RU (1) RU2126382C1 (ru)
TW (1) TW372233B (ru)
ZA (1) ZA941029B (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516653A (en) 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5668151A (en) * 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
CN1131215C (zh) * 1995-11-13 2003-12-17 赫彻斯特股份公司 环和杂环N-取代的α-亚氨基异羟肟酸和羧酸
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
US6433185B1 (en) * 1996-01-11 2002-08-13 Sanofi-Synthelabo N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
JP4106711B2 (ja) * 1996-03-21 2008-06-25 萬有製薬株式会社 アミノピリジン誘導体
ES2176776T3 (es) 1996-08-23 2002-12-01 Agouron Pharma Ligandos del neuropeptido-y.
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
EP0910565A1 (en) * 1997-02-14 1999-04-28 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
CO5011105A1 (es) * 1997-12-22 2001-02-28 Novartis Ag Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
GB2344050A (en) * 1998-11-26 2000-05-31 Ferring Bv Agents useful in the treatment of reproductive disorders.
FR2819254B1 (fr) * 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002083863A2 (en) * 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
DK1606288T3 (da) * 2003-03-25 2009-10-05 Fournier Lab Sa Benzensulfonamidderivater, fremgangsmåde til fremstilling deraf og deres anvendelse til behandling af smerte
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101679346B (zh) 2007-06-05 2014-10-22 塞诺菲-安万特股份有限公司 取代的苯甲酰氨基茚满-2-羧酸及相关化合物
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
FR2949674A1 (fr) * 2009-09-10 2011-03-11 Oreal Utilisation d'un antagoniste du neuropeptide y pour augmenter le volume et/ou la coloration naturelle des levres
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US11813268B2 (en) 2017-10-17 2023-11-14 Albert Einstein College Of Medicine Mitofusin activators and uses thereof
EP3740466B1 (en) 2018-01-17 2024-03-06 Migal Galilee Research Institute Ltd. New methionine metabolic pathway inhibitors
CN111699182A (zh) 2018-01-17 2020-09-22 米加尔-加利里研究院有限公司 新型蛋氨酸代谢途径抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT84171B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados das n alfa-aril-sulfonilamiminoacil-p- -amidinofenil-alaninamidas, bem como dos seus derivados de sintese e das composicoes farmaceuticas que os contem
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE3939797A1 (de) * 1989-12-01 1991-06-06 Basf Ag Neue vom neuropeptid y abgeleitete peptide
AU1354292A (en) * 1991-03-18 1992-10-21 Pentapharm Ag Parasubstituted phenylalanine derivates
JP3283114B2 (ja) * 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤

Also Published As

Publication number Publication date
IL108649A0 (en) 1994-05-30
TW372233B (en) 1999-10-21
FI940680A (fi) 1994-08-16
NO940503D0 (no) 1994-02-14
IL108649A (en) 1998-09-24
FI940680A0 (fi) 1994-02-14
DK0614911T3 (da) 1999-11-08
JPH06293794A (ja) 1994-10-21
US5506258A (en) 1996-04-09
ATE179430T1 (de) 1999-05-15
EP0614911A1 (fr) 1994-09-14
DE69418083D1 (de) 1999-06-02
NO304313B1 (no) 1998-11-30
KR940019682A (ko) 1994-09-14
FR2701480B1 (fr) 1995-05-24
CA2115631A1 (en) 1994-08-16
FR2701480A1 (fr) 1994-08-19
PH30887A (en) 1997-12-23
HU9400414D0 (en) 1994-05-30
RU2126382C1 (ru) 1999-02-20
HUT66960A (en) 1995-01-30
AU673398B2 (en) 1996-11-07
ZA941029B (en) 1995-08-15
NZ250878A (en) 1996-02-27
AU5516594A (en) 1994-08-18
JP2994546B2 (ja) 1999-12-27
NO940503L (ru) 1994-08-16
EP0614911B1 (fr) 1999-04-28
CN1104634A (zh) 1995-07-05
DE69418083T2 (de) 1999-11-25
GR3030243T3 (en) 1999-08-31
US5674890A (en) 1997-10-07
ES2132351T3 (es) 1999-08-16

Similar Documents

Publication Publication Date Title
MX9401191A (es) Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
ATE9695T1 (de) Antihistamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
MX9202025A (es) Nuevos compuestos di alquilen piperidino y su enantiomeros, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DE69427704T2 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
FI973279A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
MX9203972A (es) Compuestos inhibidores de la proteasa codificada por el virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulado farmaceutico que los contiene.
ES2018478B3 (es) Un sistema para preparar una composicion desensibilizante dental.
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
MX9201295A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contienen.
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
MX9201642A (es) Derivados de amidino fenil alanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
MX9204031A (es) Sal de l-ascorbato de 16-descarboxi-16-hidroximetil-amfotericina b, proceso para su preparacion y composicion farmaceutica que contiene dicha sal.
PT1057826E (pt) Derivados carboxamidicos dimericos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
MX9202300A (es) Derivados de benzofurano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2150461T3 (es) Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes.
MX9303572A (es) Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene.
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.
PT90661A (pt) Processo para a preparacao de composicoes farmaceuticas contendo inibidores da enzima conversora de angiotensina e moduladores de canal de potassio
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
MX9207269A (es) Bencimidazoles substituidos, proceso para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: NORTH CAROLINA STATE UNIVERSITY

PD Change of proprietorship

Owner name: SANOFI-SYNTHELABO

MM Annulment or lapse due to non-payment of fees